Lasting drug delivery.
Enduring vision.
A team committed to redefining ophthalmic treatment
SpyGlass Pharma brings together our industry's brightest engineers, scientists, and clinicians to develop life-changing treatment options for patients suffering from ophthalmic diseases. We are pioneering a future where sustained drug delivery simplifies chronic eye disease management, helping patients experience treatment that lasts and vision that endures.*
Our story
SpyGlass Pharma was founded in 2019 by Malik Y. Kahook, MD and Glenn Sussman to redefine the treatment of chronic ophthalmic diseases through sustained drug delivery. With more than 15 years of partnership, Malik and Glenn have combined their complementary expertise—Dr. Kahook as a leading ophthalmic surgeon, innovator, and academic, and Mr. Sussman as a medical device engineer and product development leader. Their shared vision to modernize glaucoma surgery and improve patient outcomes has driven the creation and evolution of SpyGlass Pharma.
Originating from the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine, the SpyGlass Drug Delivery Platform integrates known drugs, procedures, and devices to provide long-term disease control and vision preservation.*
Led by CEO Patrick Mooney, SpyGlass is powered by a team with deep expertise across every stage of ophthalmic innovation—from discovery to late-stage development and commercialization. With decades of experience running large-scale clinical programs and launching category-defining therapies, our leadership combines scientific rigor with proven operational excellence.
Together, we’re advancing a new era of ophthalmic care built on proven science, purposeful innovation, and enduring vision.*
Our mission
Our vision
Our guiding principles
- We create for patients
- We share responsibility
- We continuously improve
- We communicate transparently
- We embrace our differences
- We grow with agility
Our culture
We create for patients.
Our team
SpyGlass is home to industry professionals who know how to deliver meaningful change in eye care. Our scientists, engineers, and clinicians bring a wealth of experience in ophthalmology, drug delivery, and device innovation. They work with leaders who have taken therapies from early concept to clinical success and commercial launch. This is a team built to solve tough problems and bring forward therapies designed to protect vision for years to come.
SpyGlass leaders
communications, and operations expertise.
Patrick Mooney
Chief Executive Officer
Malik Y. Kahook, MD
Co-founder, President, Chief Medical Officer, and Executive Chair of the Board
James Dennewill
Chief Operating Officer
Jean-Frédéric Viret
Chief Financial Officer
Chetan Pujara, PhD
Chief Research and Development Officer
Brian Aukshunas, CPA
Vice President, Finance
Rachel Gilette
Vice President, Human Resources
Laurie Mellott
Vice President, Clinical Operations
Nina Nguyen
Senior Vice President, Regulatory & Quality
Mike Pinder
Vice President, Marketing
Anand Sundaram
Vice President, Head of Commercial
Shannon Treviño, JD
General Counsel
Paul Yoo
Senior Vice President, Clinical Development
Board of Directors
With expertise spanning academic medicine, medtech innovation, and capital markets, our board provides the strategic oversight that drives clinical rigor, operational excellence, and the advancement of sustained drug delivery.
Patrick Mooney
Chief Executive Officer
Malik Y. Kahook, MD
Co-founder, President, Chief Medical Officer, and Executive Chair of the Board
Ali Behbahani, MD
Board Director, New Enterprise Associates (NEA)
Habib J. Dable
Board Director
Michael Dybbs, PhD
Board Director, Samsara BioCapital
Bilal Khan
Board Director, New World Medical
Kirk Nielsen
Board Director, Vensana Capital
Elizabeth O’Farrell
Board Director
Geoff Pardo
Board Director, Gilde Healthcare US
Zach Scheiner, PhD
Board Director, RA Capital
Medical Advisory Board
With guidance from top ophthalmic specialists, we’re ensuring every SpyGlass innovation meets the highest standards of safety, precision, and patient care.
Robert Cionni, MD
The Eye Institute of Utah
Tom Frinzi
Health Care Advisor
Sam Garg, MD
Gavin Herbert Eye Institute/UC Irvine
Preeya Gupta, MD
Triangle Eye Consultants
Cathleen McCabe, MD
Eye Health America
Jai G. Parekh, MD, MBA, FAAO
Senior Healthcare Executive
Nathan Radcliffe, MD
New York Eye Surgery Center
Darrell White, MD
SkyVision Centers
Board Advisors
Aziz Mottiwala
Board Advisor
David Van Meter
Board Advisor